ReviewFrontiers in endocrinology2022
The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Risk factors for vertebral fractures in postmenopausal women: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Screening of osteoporosis in patients with ANCA-associated vasculitis (AAV) is quite low: results from a country-wide study.Internal and emergency medicine · 2026Article
- [Early effectiveness of total talar replacement with three-dimensional-printed talus prostheses in steroid-induced talar avascular necrosis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- Patient perspectives on glucocorticoid-associated complications and sequelae in ANCA-associated vasculitis.EULAR rheumatology open · 2025Article
- Article
- Dexamethasone synergizes with high-fat diet to increase lipid deposition in adipocytes.The Korean journal of internal medicine · 2025Article
- Review
- Treatment goals in ANCA-associated vasculitis: defining success in a new era.Frontiers in immunology · 2024Review
- The inflammatory response, a mixed blessing for muscle homeostasis and plasticity.Frontiers in physiology · 2022Review
- Comorbidities and Risk Factors Associated with Inflammatory Vasculitis in the Adult Population.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic vasculitides are a range of conditions characterized by inflammation of blood vessels which may manifest as single organ or life-threatening multisystem disease. The treatment of systemic vasculitis varies depending on the specific disease but historically has involved initial treatment with high dose glucocorticoids alone or in conjunction with other immunosuppressive agents. Prolonged glucocorticoid treatment is frequently required as maintenance treatment. Patients with small and large vessel vasculitis are at increased risk of fracture. Osteoporosis may occur due to intrinsic factors such as chronic inflammation, impaired renal function and to a large extent due to pharmacological therapy with high dose glucocorticoid or combination treatments. This review will outline the known mechanism of bone loss in vasculitis and will summarize factors attributing to fracture risk in different types of vasculitis. Osteoporosis treatment with specific consideration for patients with vasculitis will be discussed. The use of glucocorticoid sparing immunosuppressive agents in the treatment of systemic vasculitis is a significant area of ongoing research. Adjunctive treatments are used to reduce cumulative doses of glucocorticoids and therefore may significantly decrease the associated fracture risk in patients with vasculitis. Lastly, we will highlight the many unknowns in the relation between systemic vasculitis, its treatment and bone health and will outline key research priorities for this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.